© 2019 by Canterbury Scientific Ltd.

CS Ventures is the corporate venture fund initiative of Canterbury Scientific Ltd.


Canterbury Scientific Ltd is a privately-held, leading, global OEM developer and supplier of high quality in vitro diagnostic controls and calibrators for diabetes and haemoglobinopathy applications. CS Ventures was established in 2019 to invest in promising IVD opportunities that align with Canterbury Scientific’s existing capabilities.

As well as funding, CS Ventures is supported by Canterbury Scientific’s extensive experience and expertise in quality control management, and regulatory processes and approvals, including FDA and CE Mark. Canterbury Scientific is also well established in the global network of MedTech companies and works closely with many of the major players in the industry.

At CS Ventures our focus is on IVD technologies and we are scouting for opportunities globally. We are interested in a broad range of investment and partnering structures but with a preference for in-licensing technologies and earlier stage opportunities.


Robert has an invaluable combination of business, medical and research experience spanning over two decades. A qualified medical practitioner, he obtained his medical degree in London, his PhD in the Netherlands, has worked at Harvard Medical School and held clinical and academic positions at Imperial College, London. Robert is a successful serial life science entrepreneur, having founded and run three biotechnology companies in the UK before establishing the European operations for the New York based company Paramount Biosciences, LLC. Subsequently, Dr Feldman held the role of Entrepreneur in Residence at Imperial Innovations, London. In 2010, he moved to New Zealand as Executive Director of venture investment firm, Pacific Channel.

During his extensive and varied career, Robert has developed a breadth of medical and research expertise encompassing therapeutics, devices, diagnostics and functional preparations in the field of human health. In addition to Robert’s work in the UK and New Zealand, he has also engaged in business development activities in several other countries, including successful licensing deals in Europe, USA, Australia, Russia, South Korea and New Zealand.

Alice has an academic background in both biomedical science and commerce and completed her Masters of Bioscience Enterprise at the University of Auckland, New Zealand. Prior to starting at CS Ventures, Alice worked in life science partnering and R&D consulting, where she worked closely with the external innovation teams of multinational pharmaceutical, consumer health and animal health companies to help them expand their portfolios and pipelines through external collaborations and acquisitions in a range of modalities and stages of development. She also has experience in conducting extensive market analyses and on the operations side, working in accounting/finance teams.